Renowned investor Cathie Wood, chief executive of Ark Investment Management, bought shares of a biotech and a technology company focused on enabling international e-commerce. She also sold four compan...
Tag: Biotech
Big Pharma Has Enough Cash to Buy All of Biotech. Why M&A Isn’t Happening.
Text size Late last year, Barron’s predicted a wave of deals, citing biotech companies’ cash holdings. Above, the plates used to print one-dollar bills. Alex Wong/Getty Images With biotech...
Want To Save The Planet? Invest In Better Ag Policy, Not Biotech Meat
A technician displays a lab-grown chicken meat in a sealed bag at the food-tech startup SuperMeat in … [+] the central Israeli town of Ness Ziona on June 18, 2021. – It looks like chicken ...
French Biotech Company HCS Pharma Set to Raise $7.3M Through STO
French biotechnological company HCS Pharma announced today that it is set to raise $7.3 million through a security token offering (STO). HCS Pharma to Raise $7.3M Via STO In an interview with Clinical...
Biotech Stock Nkarta Skyrockets; How Its Natural Killer Cancer Drugs Did Their Job
Nkarta (NKTX) announced promising results from two studies in blood cancer patients on Monday, leading the tiny biotech stock to score a triple-digit gain. X The company tested its “natural kill...
Is Biotech ripe for investment yet?
Invezz does not provide financial advice. Our aim is to simplify information about investing, enabling each user to make educated decisions with their money and to take control of their financial futu...
Cathie Wood Watch: Ark Buys a Fascinating Tech Stock, More Biotech
Renowned investor Cathie Wood, chief executive of Ark Investment Management, on Tuesday continued her recent patterns, buying biotechnology stocks, a spectrometry stock, a 3D printer maker and a robot...
Cathie Wood Watch: Ark Buys Roku, Bulks Up on Biotech, Sells Twitter
Renowned investor Cathie Wood, chief executive of Ark Investment Management, on Monday bought shares of a top video-streaming company, several biotechnology companies and an array of other tech-relate...
it’s one of my favourite charts in biotech
Invezz does not provide financial advice. Our aim is to simplify information about investing, enabling each user to make educated decisions with their money and to take control of their financial futu...
Biotech Stocks Are Cheap. Is It Time for Blockbuster M&A?
Biotech stocks took a beating over the past 12 months, but their cheap valuations could be good entry points for investors, experts say. It could also open them up for opportunities to be acquired or ...
Biotech Stocks Could Rally – TheStreet
Biotech stocks took a beating over the past 12 months, but their cheap valuations could be good entry points for investors, experts say. The outlook for biotech stocks is positive in part because the ...
Biotech is ‘oversold’: top stocks to capitalize on the pullback
The SPDR S&P Biotech ETF is down close to 25% year-to-date but Michael Yee sees several names in this space that look promising at current valuations. Why did XBI recover in recent weeks? Interest...
Cathie Wood Buys Into a Biotech With a Covid Connection
Star investor Cathie Wood, chief executive of Ark Investment Management, has recently built a stake in a biotechnology company that earlier this month received a dose of good news. The stock is Adapti...
The Biotech Sector Nears an Inflection Point; Analysts Offer 3 Stocks to Consider
Mirroring the markets’ overall trend, the biotech sector has not gotten off to a good start in 2022, as evidenced by the Nasdaq Biotechnology Index (NBI) tilting 12% into the red year-to-date. However...
Biotech Stocks: Horizon Therapeutics Nears New Buy Point After Positive Earnings; Is It Worth Considering?
Biotech stocks to watch this week and worth considering for your portfolio include Horizon Therapeutics (HZNP). This large-cap growth stock is closing in on a potential breakout and serves as Monday&#...
Wall Street Sees Signs Battered Biotech Has Turned a Corner
(Bloomberg) — A four-day rebound in biotechnology stocks may be about to gain momentum after an industry ETF rose above a key resistance level, according to the chief strategist at Miller Tabak....
Niche Player in Biotech Space Moves Beyond Covid
You might not guess from its stock chart, but a technology supplier to the biotech industry recently argued to Jim Cramer that it’s not pandemic driven. Dr. Udit Batra, president and CEO of Wate...
Biotech Stocks: Why China-Based Plays, Like BeiGene, Are In Trouble
Regulators started a two-year clock Thursday to force China-based companies to comply with U.S. trading rules — leading three biotech stocks to crumble. X BeiGene (BGNE), Zai Lab (ZLAB) and Hutchmed (...
Cathie Wood Watch: Ark Buys Biotech Stocks
Investment star Cathie Wood, chief executive of Ark Investment Management, on Tuesday had focused some of her buying on biotechnology stocks. Recent purchases including Atai Life Sciences (ATAI) R...
VRTX Stock: Biotech Offers Bullish 2022 View After Quarterly Beat
Vertex Pharmaceuticals (VRTX) issued a bullish 2022 outlook Thursday, leading VRTX stock to approach a 12-month high. X The company expects its cystic fibrosis treatments to generate $8.4 billion to $...
Mizuho’s Vamil Divan reveals his top biotech pick
AbbVie Inc (NYSE: ABBV) closed 2021 with a 25% gain in the stock price, and Mizuho’s senior biopharmaceuticals research analyst says 2022 will be another year of outperformance for the biotech giant. ...
Biotech Stocks Are Due to Bounce Back. This One Stands Out.
Text size Large-cap biotech will offer a smoother ride than small, and Vertex, in particular, looks attractive. Igor Akimov/Dreamstime.com Biotech stocks began the year in much the same way they ended...
This biotech stock is a buy despite bearish view from BofA Securities
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was a notable beneficiary of the global pandemic that resulted in a 30% increase in its stock price last year. But BofA Securities warns 2022 will be a ver...
Here’s why the ‘biotech’ space could outperform in 2022
Invezz does not provide financial advice. Our aim is to simplify information about investing, enabling each user to make educated decisions with their money and to take control of their financial futu...
‘The capitulation model for biotech is a Category 5 storm, the same as energy in 2020’ — why contrarians say the sector is a buy
If you want to know how much investors hate the biotech sector right now, consider this simple statistic: More than 25% of small biotech companies have stock-market capitalizations that are smaller th...